From vitamin K antagonism to novel oral anticoagulants: basic concept
EHA Library. Schulman S. 06/13/14; 55593 Topic: 6Cb Anticoagulant and thrombolytic therapy in other medical conditions
Disclosure(s): Research grants from Baxter, Octapharma
Prof. Sam Schulman
Prof. Sam Schulman
Contributions
About this activity
Learning Objectives
This material is reviewed and approved by the ELC Editorial Board
After viewing this presentation the participant will be able to:

• Understand the drug development process of oral anticoagulants.
• Describe the common features of the new oral anticoagulants.
• Describe potential benefits of the new anticoagulants based on their pharmacological characteristics.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies